A Dose-finding, Pharmacokinetic, Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Phase of Trial: Phase I/II
Latest Information Update: 22 Apr 2014
At a glance
- Drugs F16 IL2 fusion protein (Primary) ; Doxorubicin
- Indications Breast cancer; Solid tumours
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Philogen
- 24 Feb 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrial.gov.
- 12 Oct 2012 Planned End Date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.